Keynote Speaker
Psilocybin and Ketamine: the Basic and Translational Science
Paul Regier
Penn’s Clinical Trial of Psilocybin for OUD
Michael Thase
How Ketamine/Esketamine Opened the Doors to Psychedelics Research
Dalibor Sames
Mechanisms of Ibogaine and Multidimensional Therapeutic Potential
Clinician’s Panel
Carlos Lopez MD
Current Modes of Ibogaine Practice in Mexico
Current Legal Frameworks
Gail Serruya MD
Clinical Delivery of Spravato and Ketamine in Real Practice
Courtney Gable
Challenges and Successes of an Independent KAT Provider
Robert Rush
Path to Deregulation in Colorado vs. DEA Scheduling of DOI.
Public and Private Coverage Models
Maurice Hinson
Andrew Cooper
Moderator
Bruno Rasmussen (Virtual)
Ibogaine’s Clinical Success in Brazil, and Legal Roadblocks Beyond Drug Scheduling
Ken Wolski
Lessons Learned from Deregulation of Marijuana in New Jersey
Psilocybin Educational Play
Neal Usatin
Producer of Netflix’s How to Change Your Mind
Emily Fischer
Leafwell, providers of cannabis therapy in all 50 states
Gaetano Lardieri
Moderator
Nichelle Santos
founder of CannaCoverage,
Trenton NJ
Sherry Rais
Enthea, provider of KAT in all 50 state
Rekha Phillip
Journey Clinical
Manufacturers Panel
Rhonda DeSantis
Psyloutions
Mattha Busby
Dalibor Sames
founder of Gilgamesh Pharmaceuticals
Patient panel
Steve Bloom
Mike Brennan
Jenny Rhubright
Jared Rinehart
Mike Holovacs
Dr. Anna Yusim
Sapan Patel
Economics of Ketamine/Esketamine
Victor Acero, PhD
Current Ibogaine Use Survey
Taweh Hunter
Current Ibogaine Use Survey
Bryan Hubbard
Complete roadmap for ibogaine implementation in Texas
